An Introduction to Hypertension
Hypertension is one of the most significant risk factors for morbidity and mortality worldwide and is responsible for the deaths of approximately 9million people each year. Despite the availability of effective treatments, many people remain with high blood pressure that is not under optimal control. Advancing technologies are likely to play an important role in improving screening, detection and control of hypertension over the next few years.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Clara Chow, ESC 2021 – the QUARTET Study
Dr Clara Chow (Professor of Medicine, Academic Director Westmead Applied Research Centre, University of Sydney, Sydney, Australia) kindly shared her thoughts on the limitations of current treatment paradigms for hypertension, the quad pill for hypertension, and the QUARTET study, from the virtual ESC Congress 2021. Questions What are the limitations of current treatment paradigms for […]
Kazem Rahimi, ESC 2021 – the Blood Pressure Lowering Treatment Trialists Collaboration
Dr Kazem Rahimi (Professor of Cardiovascular Medicine and Population Health, University of Oxford, Oxford, UK) kindly shared his thoughts on the Blood Pressure Lowering Treatment Trialists Collaboration (BPLTTC), its aims, and the benefits of antihypertensive medicines in older people from the virtual ESC Congress 2021. Questions Could you tell us a little about the Blood […]
Kazuomi Kario, ESC 2021 – the HERB Digital Therapeutics System and the HERB-DH1 Study
Prof. Kazuomi Kario (Professor, Jichi Medical University, Shimotsuke, Tochigi, Japan) kindly shared his thoughts on the HERB digital therapeutics system for essential hypertension and the HERB-DH1 study from the virtual ESC Congress 2021. Questions Could you give us a brief overview of the HERB digital therapeutics system for essential hypertension? (0.14) What were the aims, […]
Diana Bonderman, ESC 2021 – the DYNAMIC Study
Prof. Diana Bonderman (Cardiologist, Medical University of Vienna, Vienna, Austria) kindly shared her thoughts on the current challenges in the treatment of pulmonary hypertension and heart failure with preserved ejection fraction, the mechanism and use of riociguat, and the DYNAMIC study (NCT02744339) from from the virtual ESC Congress 2021. Questions What are the challenges in […]
Atrial Fibrillation and Dementia
European Journal of Arrhythmia & Electrophysiology. 2020;6(1):10-6 DOI: https://doi.org/10.17925/EJAE.2020.6.1.10
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1 AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF during their lifetime.2,3 Irrespective of age, AF incidence also increases with diabetes […]
Updates and new guidelines in statin therapy
Watch clinical specialists from Europe and the USA discuss techniques for the management and treatment of patients with high LDL-C levels, recorded during the ESC Congress 2019, Paris, France.
- Understand the importance of the ACC/AHA 2018 and ESC 2019 guidelines for management of blood cholesterol/dyslipidaemias with respect to clinical practice
- Know the risks and benefits of statin treatment with respect to the risk for type 2 diabetes
- Understand the potential for abnormal liver function and metabolic syndrome and be aware of drug-drug interaction as most statins are metabolized via the cytochrome P450 pathway
- Know that the PROVE IT and REAL-CAD trials show that high-dose statin therapy is superior to moderate or low dose in cardiovascular event reduction
- Understand that combination therapy gives an additional reduction in LDL levels and that statin dose should be titrated to risk
Renal Denervation in High-risk Patients with Hypertension
Heart International. 2019;13(2):12-6 DOI: https://doi.org/10.17925/HI.2019.13.2.12
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular disease and end-stage renal disease.2 Renal denervation (RD) is an emerging treatment modality which allows […]
Jean-François Obadia, ESC 2019 – Follow up from the MITRA-FR Trial
We spoke to Professor Jean-François Obadia (Civils Hospices of Lyon, Lyon, France) about the 2-year follow up from the MITRA-FR trial, and how he would interpret the differing results from recent studies into the efficacy of the MitraClip in patients with mitral regurgitation. Finally, he touches on which patients might be likely to benefit from […]
J Jaime Miranda, ESC 2019 – Blood Pressure and Community Hypertension
We spoke to Dr J Jaime Miranda (School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru) about hypertension and the impact of introducing a low-sodium, high-potassium salt substitute on the incidence of community hypertension. He also then went on to discuss effective ways to improve control of high blood pressure in high- and low-income countries. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!